Literature DB >> 12234504

Long-term follow-up of radical retropubic prostatectomy for prostate cancer.

G P Swanson1, M W Riggs, J D Earle, M G Haddock.   

Abstract

OBJECTIVES: The ultimate outcome of patients after radical prostatectomy is often predicted from statistical projections of short-term follow-up. Only actual long-term follow-up can demonstrate true outcome.
METHODS: One hundred thirty-one patients underwent retropubic prostatectomy for clinically organ confined prostate cancer and have been followed for a minimum of 22.5 years. Preoperatively, all but 12 had clinically palpable cancer.
RESULTS: Overall survival in these patients was similar to an age-matched population, with 65% alive at 15 years, and 23% alive at 25 years. Thirty-seven percent of the patients recurred and 24% of all the patients died of prostate cancer. For patients with pathologically organ confined disease, 27% recurred, while those with extension outside the gland or positive nodes had an 83% recurrence rate. Although, the median time to recurrence was 7 years, recurrences occurred at a steady-state throughout the length of follow-up. Patients with higher grade tumors, even if organ confined, were significantly more likely to recur.
CONCLUSIONS: In a cohort of patients treated with radical prostatectomy for predominantly palpable disease, long-term follow-up (79% deceased) reveals that 37% will recur and 24% will die of prostate cancer. Almost half the recurrences occurred after 10 years, indicating that reports with shorter follow-up will underestimate the recurrence rate.

Entities:  

Mesh:

Year:  2002        PMID: 12234504     DOI: 10.1016/s0302-2838(02)00276-2

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  6 in total

1.  Circulating MicroRNA as Biomarkers: An Update in Prostate Cancer.

Authors:  Anvesha Srivastava; Simeng Suy; Sean P Collins; Deepak Kumar
Journal:  Mol Cell Pharmacol       Date:  2011

2.  Costs of early adjuvant radiation therapy after radical prostatectomy: a decision analysis.

Authors:  T N Showalter; K A Foley; E Jutkowitz; C D Lallas; E J Trabulsi; L G Gomella; A P Dicker; L T Pizzi
Journal:  Ann Oncol       Date:  2011-06-09       Impact factor: 32.976

3.  Physician beliefs and practices for adjuvant and salvage radiation therapy after prostatectomy.

Authors:  Timothy N Showalter; Nitin Ohri; Kristopher G Teti; Kathleen A Foley; Scott W Keith; Edouard J Trabulsi; Costas D Lallas; Adam P Dicker; Jean Hoffman-Censits; Laura T Pizzi; Leonard G Gomella
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-05-24       Impact factor: 7.038

4.  Controversies on individualized prostate cancer care: gaps in current practice.

Authors:  Steven Joniau; David Pfister; Alexandre de la Taille; Franco Gaboardi; Alan Thompson; Maria J Ribal
Journal:  Ther Adv Urol       Date:  2013-10

Review 5.  Long-term results after external beam radiation therapy for T1-T2 localized prostate cancer.

Authors:  B W Lagerveld; M P Laguna; J J M C H de la Rosette
Journal:  Curr Urol Rep       Date:  2003-06       Impact factor: 2.862

6.  Performance evaluation of Cerenkov luminescence imaging: a comparison of 68Ga with 18F.

Authors:  J Olde Heuvel; B J de Wit-van der Veen; K N Vyas; D S Tuch; M R Grootendorst; M P M Stokkel; C H Slump
Journal:  EJNMMI Phys       Date:  2019-10-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.